Douglas Earl Martin
SEC insider (Form 3/4/5 filer). CIK 0001362155. SVP, General Counsel at Allogene Therapeutics, Inc. (ALLO). 6 reported Form 4/5 transactions since Sep 2024; latest on Aug 21, 2026. Located in SOUTH SAN FRANCISCO, CA.
Companies Douglas Earl Martin has filed insider reports for
- Allogene Therapeutics, Inc. (ALLO): Officer, SVP, General Counsel
Douglas Earl Martin
CIK: 0001362155
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Allogene Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Aug 21, 2026ALLO
Allogene Therapeutics, Inc.
SaleDirect29.7K shares at avg. $2.12$63K - Feb 2, 2026ALLO
Allogene Therapeutics, Inc.
SaleDirect22.9K shares at avg. $1.76$40K - Feb 2, 2026ALLO
Allogene Therapeutics, Inc.
AwardDirectStock Option (Right to buy)
539.1K shares- - Feb 2, 2026ALLO
Allogene Therapeutics, Inc.
AwardDirectRestricted Stock Unit
152.5K shares- - Feb 3, 2025ALLO
Allogene Therapeutics, Inc.
SaleDirect6.4K shares at avg. $1.71$11K - Jan 24, 2025ALLO
Allogene Therapeutics, Inc.
AwardDirect144.9K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 21, 2026 | ALLO Allogene Therapeutics, Inc. | Sale | 29,697 | $2.12 | $62,958 | Direct |
| Feb 2, 2026 | ALLO Allogene Therapeutics, Inc. | Sale | 22,900 | $1.76 | $40,304 | Direct |
| Feb 2, 2026 | ALLO Allogene Therapeutics, Inc. | Award Stock Option (Right to buy) | 539,072 | - | - | Direct |
| Feb 2, 2026 | ALLO Allogene Therapeutics, Inc. | Award Restricted Stock Unit | 152,480 | - | - | Direct |
| Feb 3, 2025 | ALLO Allogene Therapeutics, Inc. | Sale | 6,404 | $1.71 | $10,951 | Direct |
| Jan 24, 2025 | ALLO Allogene Therapeutics, Inc. | Award | 144,928 | - | $0 | Direct |
1-6 of 6 transactions